| Entry |
|
|---|
| Name |
Capecitabine (JAN/USP/INN);
Xeloda (TN)
|
|---|
| Product |
|
|---|
| Generic |
CAPECITABINE (Accord Healthcare), CAPECITABINE (American Health Packaging), CAPECITABINE (Amneal Pharmaceuticals LLC), CAPECITABINE (Areva Pharmaceuticals), CAPECITABINE 150MG (Armas Pharmaceuticals), CAPECITABINE 500MG (Armas Pharmaceuticals), CAPECITABINE (Ascend Laboratories), CAPECITABINE (Aurobindo Pharma Limited), CAPECITABINE (AvPAK), CAPECITABINE (CELLTRION USA), CAPECITABINE (Cipla USA), CAPECITABINE (Golden State Medical Supply), CAPECITABINE (MSN LABORATORIES PRIVATE LIMITED), CAPECITABINE (Mylan Institutional), CAPECITABINE (Mylan Pharmaceuticals), CAPECITABINE (Northstar RxLLC), CAPECITABINE (Novadoz Pharmaceuticals LLC), CAPECITABINE (Rising Pharmaceuticals), CAPECITABINE (Sun Pharmaceutical Industries), CAPECITABINE (Teva Pharmaceuticals USA), CAPECITABINE (West-Ward Pharmaceuticals Corp.) |
|---|
| Formula |
C15H22FN3O6
|
|---|
| Exact mass |
359.1493
|
|---|
| Mol weight |
359.3501
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
Antineoplastic
DG01958 Nucleic acid derivative, antineoplastic
DG01439 Arabinofuranosyl type antineoplastic
DG01935 Fluoropyrimidine antineoplastic
DG01439 Arabinofuranosyl type antineoplastic
DG01935 Fluoropyrimidine antineoplastic
DG02018 Antimetabolite
DG01958 Nucleic acid derivative, antineoplastic
DG01439 Arabinofuranosyl type antineoplastic
DG01935 Fluoropyrimidine antineoplastic
Metabolizing enzyme substrate
DG01642 CYP2C9 substrate
|
|---|
| Remark |
| Therapeutic category: | 4223 |
|
|---|
| Efficacy |
Antineoplastic, Antimetabolite |
|---|
| Disease |
|
|---|
| Comment |
Active form of prodrug: Fluorouracil [DR: D00584]
|
|---|
| Target |
|
|---|
| Pathway |
|
|---|
| Metabolism |
Enzyme: CYP2C9 [HSA: 1559]
|
|---|
| Interaction |
|
|---|
| Structure map |
| map07041 | Antineoplastics - antimetabolic agents |
|
|---|
| Other map |
| map00983 | Drug metabolism - other enzymes |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01B ANTIMETABOLITES
L01BC Pyrimidine analogues
L01BC06 Capecitabine
D01223 Capecitabine (JAN/USP/INN) <JP/US>
USP drug classification [BR:br08302]
Antineoplastics
Antimetabolites
Capecitabine
D01223 Capecitabine (JAN/USP/INN)
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
42 Antineoplastics
422 Antimetabolites
4223 Fluorouracils
D01223 Capecitabine (JAN/USP/INN)
Target-based classification of drugs [BR:br08310]
Enzymes
Transferases (EC2)
Methyltransferases
TYMS
D01223 Capecitabine (JAN/USP/INN) <JP/US>
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D01223
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D01223
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D01223
Pharmacogenomic biomarkers [br08341.html]
Polymorphisms and mutations affecting drug response
D01223
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 25
1 C1y C 11.2700 -21.5600
2 C1y C 12.6700 -21.5600
3 C1y C 13.1600 -20.2300
4 O2x O 11.9700 -19.4600
5 C1y C 10.8500 -20.2300
6 C1a C 9.5200 -19.8100
7 O1a O 10.4300 -22.7500
8 O1a O 13.5100 -22.7500
9 N4y N 14.4900 -19.8100
10 C8y C 15.6800 -20.5100
11 N5x N 16.9400 -19.8100
12 C8y C 16.9400 -18.4100
13 C8y C 15.7500 -17.7100
14 C8x C 14.4900 -18.4100
15 O5x O 15.6800 -21.9100
16 X F 15.7500 -16.3800
17 N1b N 18.1300 -17.7100
18 C7a C 19.3200 -18.4100
19 O7a O 20.5100 -17.7100
20 C1b C 21.7000 -18.4100
21 C1b C 22.8900 -17.7100
22 C1b C 24.0800 -18.4100
23 C1b C 25.2700 -17.7100
24 C1a C 26.4600 -18.4100
25 O6a O 19.3200 -19.8100
BOND 26
1 1 2 1
2 2 3 1
3 3 4 1
4 4 5 1
5 1 5 1
6 5 6 1 #Up
7 1 7 1 #Down
8 2 8 1 #Down
9 3 9 1 #Up
10 9 10 1
11 10 11 1
12 11 12 2
13 12 13 1
14 13 14 2
15 9 14 1
16 10 15 2
17 13 16 1
18 17 18 1
19 17 12 1
20 18 19 1
21 19 20 1
22 20 21 1
23 21 22 1
24 22 23 1
25 23 24 1
26 18 25 2
|
|---|
